Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 3
2021 5
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S, Guida M, Di Fonte R, De Summa S, Strippoli S, Iacobazzi RM, Quarta A, De Risi I, Guida G, Paradiso A, Porcelli L, Azzariti A. Serratì S, et al. Among authors: de risi i. Mol Cancer. 2022 Jan 18;21(1):20. doi: 10.1186/s12943-021-01490-9. Mol Cancer. 2022. PMID: 35042524 Free PMC article.
Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
Serratì S, Di Fonte R, Porcelli L, De Summa S, De Risi I, Fucci L, Ruggieri E, Marvulli TM, Strippoli S, Fasano R, Rafaschieri T, Guida G, Guida M, Azzariti A. Serratì S, et al. Among authors: de risi i. J Exp Clin Cancer Res. 2023 Sep 28;42(1):251. doi: 10.1186/s13046-023-02808-9. J Exp Clin Cancer Res. 2023. PMID: 37759291 Free PMC article.
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Rubatto M, Fava P, Stanganelli I, Ribero S, Pigozzo J, Di Giacomo AM, Ridolfi L, Tronconi MC, Trojaniello C, Bersanelli M, Garutti M, Indini A, De Risi I, De Tursi M, Merelli B, Morgese F, Occelli M, Cappellini GCA, Poletto S, Fedele D, Brugnara S, Frisinghelli M, Formisano L, Conca R, Tucci M, Russillo M, Ceroni L, Queirolo P, Targato G, Strippoli S, Mandalà M, Guida M, Quaglino P. Rubatto M, et al. Among authors: de risi i. Eur J Cancer. 2023 Jul;187:25-35. doi: 10.1016/j.ejca.2023.03.020. Epub 2023 Mar 23. Eur J Cancer. 2023. PMID: 37099946
The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma.
Guida M, Bartolomeo N, De Risi I, Fucci L, Armenio A, Filannino R, Ruggieri E, Macina F, Traversa M, Nardone A, Figliuolo F, De Luca F, Mele F, Tommasi S, Strippoli S. Guida M, et al. Among authors: de risi i. Cancers (Basel). 2019 Oct 14;11(10):1559. doi: 10.3390/cancers11101559. Cancers (Basel). 2019. PMID: 31615127 Free PMC article.
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
Guida M, Bartolomeo N, Quaresmini D, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, Ridolfi L, Queirolo P, De Risi I, Valente M, Sciacovelli AM, Chiarion Sileni V, Ascierto PA, Stigliano L, Strippoli S. Guida M, et al. Among authors: de risi i. J Transl Med. 2022 Apr 5;20(1):159. doi: 10.1186/s12967-022-03359-x. J Transl Med. 2022. PMID: 35382857 Free PMC article.
18 results